Evidence map›Paper›PMID 25166211›Full record

ArticlePloS one2014

Hypoxia promotes uveal melanoma invasion through enhanced Notch and MAPK activation.

Laura Asnaghi, Michael H Lin, Kah Suan Lim, Kah Jing Lim, Arushi Tripathy, Murilo Wendeborn, Shannath L Merbs, James T Handa, Akrit Sodhi, Eli E Bar and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Hypoxia-dependent drivers of melanoma progression.Journal of experimental & clinical cancer research : CR · 2021
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Laura AsnaghiDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America.
Michael H LinDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America.
Kah Suan LimDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America.
Kah Jing LimDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America.
Arushi TripathyDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America.
Murilo WendebornDepartment of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America.
Shannath L MerbsDepartment of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America; Department of Oncology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America.
James T HandaDepartment of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America.
Akrit SodhiDepartment of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America.
Eli E BarDepartment of Neurological Surgery, School of Medicine, Case Western Reserve University, Cleveland, Ohio, United States of America.
Charles G EberhartDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America; Department of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America; Department of Oncology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States of America.
Johns Hopkins Medicine · USJohns Hopkins University · USCase Western Reserve University · US

Funding

HIF dysregulation as a novel genetic model to study retinal neovascular disease.K08EY021189 · NEI · JOHNS HOPKINS UNIVERSITY · PI SODHI, AKRIT SINGH · 2011 to 2015
$898k
NEI NIH HHS K08 EY021189
6 · The paper itself

Abstract

The transcriptional response promoted by hypoxia-inducible factors has been associated with metastatic spread of uveal melanoma. We found expression of hypoxia-inducible factor 1α (HIF-1α) protein in well-vascularized tumor regions as well as in four cell lines grown in normoxia, thus this pathway may be important even in well-oxygenated uveal melanoma cells. HIF-1α protein accumulation in normoxia was inhibited by rapamycin. As expected, hypoxia (1% pO2) further induced HIF-1α protein levels along with its target genes VEGF and LOX. Growth in hypoxia significantly increased cellular invasion of all 5 uveal melanoma lines tested, as did the introduction of an oxygen-insensitive HIF-1α mutant into Mel285 cells with low HIF-1α baseline levels. In contrast, HIF-1α knockdown using shRNA significantly decreased growth in hypoxia, and reduced by more than 50% tumor invasion in four lines with high HIF-1α baseline levels. Pharmacologic blockade of HIF-1α protein expression using digoxin dramatically suppressed cellular invasion both in normoxia and in hypoxia. We found that Notch pathway components, including Jag1-2 ligands, Hes1-Hey1 targets and the intracellular domain of Notch1, were increased in hypoxia, as well as the phosphorylation levels of Erk1-2 and Akt. Pharmacologic and genetic inhibition of Notch largely blocked the hypoxic induction of invasion as did the pharmacologic suppression of Erk1-2 activity. In addition, the increase in Erk1-2 and Akt phosphorylation by hypoxia was partially reduced by inhibiting Notch signaling. Our findings support the functional importance of HIF-1α signaling in promoting the invasive capacity of uveal melanoma cells in both hypoxia and normoxia, and suggest that pharmacologically targeting HIF-1α pathway directly or through blockade of Notch or Erk1-2 pathways can slow tumor spread.

Indexed as

Cell Line, TumorDigoxinEnzyme InhibitorsHumansHypoxiaHypoxia-Inducible Factor 1, alpha SubunitMAP Kinase Signaling SystemMelanomaNeoplasm InvasivenessProto-Oncogene Proteins c-aktReceptors, NotchSignal TransductionUveal NeoplasmsDigoxinEnzyme InhibitorsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitProto-Oncogene Proteins c-aktReceptors, Notch

Identifiers

PMID25166211
PMCPMC4148307
OpenAlexW2091450314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.